In comparison to the standard care group, the NT-proBNP-guided method in HF patients did not significantly reduce cardiovascular mortality or the time to initial hospitalization, according to a study by Felker et al. Thus, it is encouraged to conduct more clinical trials examining the prognosis of heart failure patients receiving PENK-guided treatment [6]. This evidence concerns the gene NPPB and heart failure.